1. Home
  2. FAX vs RIGL Comparison

FAX vs RIGL Comparison

Compare FAX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAX
  • RIGL
  • Stock Information
  • Founded
  • FAX 1986
  • RIGL 1996
  • Country
  • FAX United States
  • RIGL United States
  • Employees
  • FAX N/A
  • RIGL N/A
  • Industry
  • FAX Investment Managers
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAX Finance
  • RIGL Health Care
  • Exchange
  • FAX Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • FAX 632.9M
  • RIGL 537.6M
  • IPO Year
  • FAX N/A
  • RIGL 2000
  • Fundamental
  • Price
  • FAX $15.36
  • RIGL $51.48
  • Analyst Decision
  • FAX
  • RIGL Strong Buy
  • Analyst Count
  • FAX 0
  • RIGL 5
  • Target Price
  • FAX N/A
  • RIGL $43.20
  • AVG Volume (30 Days)
  • FAX 833.6K
  • RIGL 774.9K
  • Earning Date
  • FAX 01-01-0001
  • RIGL 11-04-2025
  • Dividend Yield
  • FAX 12.09%
  • RIGL N/A
  • EPS Growth
  • FAX N/A
  • RIGL 2698.26
  • EPS
  • FAX N/A
  • RIGL 6.20
  • Revenue
  • FAX N/A
  • RIGL $282,076,000.00
  • Revenue This Year
  • FAX N/A
  • RIGL $59.93
  • Revenue Next Year
  • FAX N/A
  • RIGL N/A
  • P/E Ratio
  • FAX N/A
  • RIGL $8.24
  • Revenue Growth
  • FAX N/A
  • RIGL 79.13
  • 52 Week Low
  • FAX $2.33
  • RIGL $14.63
  • 52 Week High
  • FAX $2.84
  • RIGL $51.73
  • Technical
  • Relative Strength Index (RSI)
  • FAX 50.18
  • RIGL 73.90
  • Support Level
  • FAX $14.83
  • RIGL $34.00
  • Resistance Level
  • FAX $15.55
  • RIGL $50.23
  • Average True Range (ATR)
  • FAX 0.21
  • RIGL 3.08
  • MACD
  • FAX 0.02
  • RIGL 1.13
  • Stochastic Oscillator
  • FAX 79.17
  • RIGL 96.45

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: